Hep B biotech Antios closed after FDA hold proved insurmountable

Viral disease biotech Antios Therapeutics shut down earlier this year after an FDA hold on its lead hepatitis B therapy due to a serious adverse event proved insurmountable. | Viral disease biotech Antios Therapeutics shut down earlier this year after an FDA hold on its lead hepatitis B therapy due to a serious adverse event proved insurmountable.

Engineering Biomimetic Extracellular Matrix with Silica Nanofibers

Assembly Bio ends hepatitis B alliance after FDA hold on partner

IHEP (International Hepatology Education Program)

Press Release: Novartis suspends US marketing and sales of Zelnorm

Biotech Fierce Biotech

Hepatitis B drug developers chart slow progress, just like in hep C

Heart trouble report & clinical hold spell end of Antios, Assembly

Annalee Armstrong - Journalist Profile - Intelligent Relations

Antios hep B drug slows viral rebound, but FDA hold casts shadow

Hepatitis B Foundation